The Anatolian Journal of Cardiology

[Anatol J Cardiol]
Anatol J Cardiol. 2008; 8(Suppl. 2): 131-147

Heart transplantation

Ozan Erbasan, Cemal Kemaloğlu, Ömer Bayezid
Department of Cardiovascular Surgery, Faculty of Medicine, Akdeniz University, Antalya, Turkey

End-stage heart failure is still associated with a decrease in both quality and prognosis of life and one- year survival of these patients is below 50%. Heart transplantation remains the final therapeutic option for the treatment of irreversible end-stage heart failure in all age groups with adequate success rates. Survival of patients who underwent heart transplantation has improved incrementally in recent years, with 86% survival in the first year and over 50% survival at 10 years. Approximately 50% of patients live for more than 10 years after heart transplantation and 25% of patients live for more than 18 years. Improvement of the quality of life is an other benefit, while the patients were in NYHA class III-IV preoperatively, nearly all of them have an improved functional status with NYHA class I-II after transplantation. However, discrepancy between the number of candidates and number of available donors is still the major problem for the applicability of heart transplantation.

Keywords: heart transplantation, immunosuppression, rejection, cardiac allograft vasculopathy, endomyocardial biopsy


Ozan Erbasan, Cemal Kemaloğlu, Ömer Bayezid. Heart transplantation. Anatol J Cardiol. 2008; 8(Suppl. 2): 131-147

Sorumlu Yazar: Ozan Erbasan, Türkiye


ARAÇLAR
Tam Metin PDF
Yazdır
Alıntıyı İndir
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
E-Postala
Paylaş
Yazara e-posta gönder

Benzer makaleler
PubMed
Google Scholar